Cooperative Agreement U01CA295226
Award Date
3/19/25
Completion Date
2/28/30
Dollars Obligated
$440K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Cooperative Agreement
Place of Performance
Washington, USA
Similar Awards
This Cooperative Agreement award of $356,850 from the National Cancer Institute (NCI), under the Cancer Treatment Research grant program (CFDA 93.395), aims to establish pre-analytical sample processing guidelines to enable maximal reproducibility for functional testing outcomes in liquid biopsy-based cancer research and clinical testing.
The project, led by Oregon Health & Science University (OHSU), focuses on characterizing the pre-analytical steps involved in blood and bone marrow...
The National Cancer Institute (NCI) awarded a $401,113 Cooperative Agreement grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Washington. The funding will support the development and clinical testing of the METABOCORE assay, which aims to rapidly evaluate drug sensitivity of solid tumor samples obtained through needle biopsies. The key objectives are to optimize the assay's preanalytical parameters, such as biopsy methods, transport conditions, and culture...
This $440,287 Project Grant awarded by the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) aims to establish a simplified and accessible procedure for simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This research will leverage tumor touch imprints on glass slides as a biobanking method, in combination with a multi-analyte molecular extraction protocol previously developed for forensic applications. The key products or services to be...
This Project Grant award of $465,028 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will fund research to advance functional mass spectrometry imaging (FMSI) methodology for monitoring dynamic physiological processes in tissues. The key products and services to be delivered include:
Evaluating bolus and constant infusion protocols for isotopologue administration to improve sensitivity and extend the observable metabolic window of the FMSI technique....
This Project Grant award from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) provides $652,799 to the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to investigate the role of oncogenic MAPK signaling in causing a lethal form of kinetochore stress in glioblastoma. The research aims to reveal mechanistic details of this 'MASKS' model, evaluate its relevance in patient tumors, and elucidate associated vulnerabilities in cancer...
The National Cancer Institute (NCI) awarded a $554,653 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Institute for Systems Biology in Seattle, Washington. The grant, titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES", seeks to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs) in liquid and tissue...
This $335,944 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports the further development, refinement, and validation of the awardee's free-solution assay (FSA) technology and compensated interferometric reader (CIR). This novel, label-free, and solution-phase platform represents a paradigm-shifting approach to quantify molecular interactions relevant to cancer research and clinical applications. The FSA-CIR system enables...
This federal Project Grant award from the National Cancer Institute (under CFDA 93.394 - Cancer Detection and Diagnosis Research program) provides $671,072 to the University of Washington to develop a novel ultra-miniaturized "picoliter thin-layer chromatography (PTLC) chip" and supporting instrumentation. The goal is to create an integrated microdevice that can measure malignant lipid signaling in single cells from clinical samples with enhanced sensitivity and throughput compared...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $240,092 to the Scripps Research Institute to develop new mass spectrometry-based protein footprinting techniques to measure protein conformations and protein-protein interactions at the single cell level.
The key objectives are to implement "covalent protein painting" (CPP) methods that can quantify lysine site accessibility in single cells, as well as a...
This $1,128,990 Cooperative Agreement awarded by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) supports the Dana-Farber Cancer Institute's "Myeloma Multidimensional Precancer Atlas" (MMPCA) project. The project aims to construct a comprehensive spatial and temporal atlas of the transition from healthy cells to multiple myeloma, a type of blood cancer. Specifically, the research will map the interactions...